The receptor tyrosine kinase-like orphan 1 (ROR1) is a transmembrane protein expressed during embryonic development. Moreover, it is highly expressed on the surface of several cancer cell types, including B-cell malignancies and solid tumors such as triple-negative breast cancer (TNBC). Researchers from The University of Queensland and collaborating institutions recently reported the development of a single-chain fragment variable (scFvs) specifically targeting the membrane proximal region of ROR1 rather than the Ig-like domain, aiming to reduce cross-reactivity with other surface proteins expressed in normal tissues.
Shanghai Henlius Biotech Inc. has announced acceptance of IND applications by China’s National Medical Products Administration (NMPA) for three differentiated candidates for the treatment of solid tumors.
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was reported, with innovations spanning targets, linkers, payloads, conjugation chemistries and overall architectures. Once defined by a simple “one target, one payload” model, the field is lately expanding into a more versatile and diverse therapeutic space.
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. raised HK$586 million (US$75.37 million) in its IPO on the Hong Kong Securities Exchange (HKEX:3378) on Dec. 23 to advance its clinical stage immuno-oncology pipeline.
Hanx Biopharmaceuticals Inc. has identified antibody-drug conjugates (ADCs) consisting of an antibody targeting TRBV12 covalently linked to cytotoxic drugs through linkers reported to be useful for the treatment of T-cell leukemia and T-cell lymphoma.
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR T candidate, named GT-801.
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. raised HK$586 million (US$75.37 million) in its IPO on the Hong Kong Securities Exchange (HKEX:3378) on Dec. 23 to advance its clinical stage immuno-oncology pipeline.
Jiangsu Simcere Biologics Co. Ltd. has disclosed antibody-drug conjugates (ADC) comprising an antibody huAb-H3aL3-IgG1 targeting cadherin-17 (CDH17) covalently linked to a camptothecin derivative through a linker reported to be useful for the treatment of cancer.
Simcere Zaiming Pharmaceutical Co. Ltd. has obtained clinical trial approval from China’s National Medical Products Administration (NMPA) for SIM-0610 to be studied in patients with locally advanced or metastatic solid tumors.
IMV-101 is a new CAR T-cell therapy targeting CD19 developed by Suzhou Immunofoco Biotechnology Co. Ltd. for the potential treatment of B-cell malignancies and autoimmune diseases. The company has presented results of the evaluation of its in vitro and in vivo properties.
RSS
